Interim report
Page 1
SENZA GEN JANUARY - JUNE 2026 INTERIM REPORT Q2 Continued strong development in Q2 2026-13 % growth with positive cash flow " Revenue for the second quarter increased to SEK 15.3 million , corresponding to 13 % growth ( 18 % at constant exchange rates ) . At the same time , we maintained an effective cost base and achieved a gross margin in line with our historical levels . We are particularly pleased with the strong cash flow performance from operating activities , which was positive during the quarter . The turnaround at VitroScreen is progressing with order intake increasing both sequentially and year - on - year , and we have received two major orders . Together with favorable regulatory developments and our ongoing strategic initiatives , this creates a strong platform for long - term profitable growth . " Peter Nählstedt , President and CEO Significant events during the second quarter • • The Group's subsidiary VitroScreen received a strategically important order worth approximately SEK 0.6 million for non - animal efficacy testing using the proprietary VitroScreenORAⓇ test platform . VitroScreen also received orders with a total value of approximately SEK 2.4 million from two existing customers , with revenue recognition expected toward the end of 2026 . The EU has recently presented a roadmap towards phasing out animal testing , which is expected to strengthen the long - term market prospects for SenzaGen's non - animal testing solutions . Significant events after the end of the period • No significant events have occurred after the end of the reporting period . 2026 2025 Change 2026 2025 Change SEK M Apr - Jun Apr - Jun % Jan - Jun Jan - Jun % 2025 Jan - Dec Revenue 15.3 13.5 13 30.2 27.2 11 58.0 GARD® 10.5 9.6 9 21.5 19.1 13 41.9 Gross margin , % 66 64 2 pts 68 70 -2 pts 65 EBITDA -1.2 -3.9 69 -2.9 -5.9 51 -8.8 EBIT -2.1 -4.4 53 -4.2 -6.6 36 -11.6 Earnings / loss per share , SEK -0.07 -0.13 46 -0.13 -0.22 41 -0.39 Cash and cash equivalents 35.5 34.4 3.0 35.5 34.4 3.0 26.8 SenzaGen AB • January - June 2026 Interim Report • 1/17